Member Info for Toyin

Rebalm, that theory came from Ashman which we can all agree should be taken with a pinch of salt. Hishda (senior marketing Croda) stated last year after launch that Zenakine and Matrixyl were not in competition.

Regarding the planet and sustainability Croda research and other research would disagree with your view but we could argue that all day.

Matrixyl went green last year with Matrixyl 3000glyx (but not 100% green). Matrixyl Neolide is just a new delivery system from what I can see, it is greener, natural origin content 99.79% but when processed drops to 83.88% (Zenakine is 100%). Zenakine is still the clear leader in the green department.

We also know that Skinbiotix does reduce wrinkles but they aren’t going to step on Matrixyl’s toes just yet, that is why they have marketed it the way they have, it will be a slow transition, you cant swop diehard users that quickly, its commercial suicide. Regarding sleeping tablets thats your call.

If you compare the consumer benefits, Zenakine is a clear winner.

Matrixyl Neolide Consumer benefit:

Anti-ageing

Zenakine Consumer benefit:

Anti-ageing

Calming / soothing / redness

Environmental protection

Revitalising

Physiological balance

The investigation will be what it will be, no point second guessing like some, it just sends your brain down the wrong path.

Regarding Zenakine sales nobody knows, what we do know is, as shy points out, the chair gave us a mention, Croda have described it as “groundbreaking” and “redefining the future of neurocosmetics” they have just launched a new formulation, customers have launched in Europe and Asia and they have just rolled it out into North America. Just yesterday Croda stated beauty actives continued to deliver a strong performance, driven by renewed customer appetite for innovation (Zenakine is in that space), that doesnt sound like anyone is pulling any plugs, in fact quite the opposite.

Rebarm, what gives you that impression?

Sales in Consumer Care were up 4% on a constant currency basis. Beauty Actives continued to deliver a strong performance, with growth in all regions at constant currency driven by renewed customer appetite for innovation and continued spending by higher-income households.

Mol, if it is absolute nonsense and there is absolutely no point, why comment?

I requested permission to share before I posted, do you honestly believe the new management would send me information and then say that they were happy for me to share, if it was nonsense!

Instead of guessing, why dont you ask the question.

Take it up with the company mol. ir@skinbiotix.com

On 20 Apr 2026, at 17:04, IR <ir@skinbiotix.com> wrote:

This is a routine filing with Companies House relating to the loan from Mr Brierwood announced on 11 October 2024 (here).

SkinBioTherapeutics IR team

Now avalible in North America.

https://www.crodabeauty.com/en-gb/products/product/5852-zenakine

Net, I’m very happy for you.

It’s not about liking or disliking your comments, it’s about if they are constructive and factually correct, which in this instance they weren’t. You commented on something which you openly admitted you didn’t understand (PLE, which was a crucial element of the discussion) whilst trying to discredit Aquae’s post.

I suggest in future you read, inwardly digest and think before you hit the tippy tappy!

Net, if you don’t know what PLE is, why are you even commenting?

No net, the same thing doesn’t apply. Your comment was in relation to Zenakine, Aquae’s post was nothing to do with Zenakine, you were to quick to judge instead of looking into the information Aquae posted.

Instead of trying to squirm out of it, just say sorry Aquae, great post, thanks for the information.

Thanks Aquae, very interesting.

net, this is nothing to do with Zenakine, its a completely different kind of bacteria.

Whackery, we first have to understand what “material miss” actually means, is it 3%, 5%,10%?

Secondly, if you look at the wording in the rns 16/2, it states "Dermatonics and Bio-Tech Solutions are operating as reported at FY25 (audited revenues of £2.20m and £1.38m respectively) and both are trading at cash breakeven. These businesses are trading in line with the current Board's expectations for FY26. Note it states “current boards expectations” which suggest to me they have been downgraded.

We may see some growth especially within BTS due to it manufacturing Derma products now (if those synergies have actually been realised, allegedly these synergies take many years!)

I think the material miss statement is down to the acquisitions, hence the “current board” statement. The acquisitions are what they are and Axis has been let down by poor management, they all need rebasing from the previous BOD’s pipe dreams.

Regarding Croda they will stay as far away from this as possible and I dont blame them. Zenakine is the only reason I am here, Croda customers have launched in Asia and Europe and I am comfortable with that.

Hi Ox123, I cant see there being a "milestone volume/value” that would be a material piece of information and there is no mention of it in any rns.

"The terms are based on the original agreement with SkinBioTherapeutics being paid tiered royalties based on global sales revenues on any licensed products derived from the partnership."

Call me the eternal optimist but I am going with your latter explanation, timing = misrepresented material information, fabricating = fraud. I just think he needed it so badly to try and lessen the blow on the acquisitions, he lost his head made a bad call and then just kept digging. Can you imagine if he put out FY25 revenue of £3.87m, his bo11ox would have been on the block faster than you could say "misrepresented material information” he knew he was fooked, it was his only play.

Thanks Aquae, wholeheartedly agree.

Whackery, I would just like to add, I think the “material miss” statement is part of the kitchen sink job by the new BOD, after all, that statement was made four and a half months before the end of FY26, how can they possibly know what Croda sales of Zenakine will be up to the end of June 26, they dont, its impossible.

Thanks shy. I’m not fussy, I will take any potential revenue stream Croda see fit to launch.

We now have a seventh formulation, this time formulated in Brazil.

https://www.crodabeauty.com/en-gb/formulations/formulation/8656-night-harmony-regeneration

Well worth a read. Registration required.

https://www.gcimagazine.com/ingredients/skin-care/article/22961650/molecular-longevity-and-the-neurourban-shield-the-2026-beauty-ingredient-agenda?utm_source=newsletter-html&utm_medium=email&utm_campaign=GCI+E-Newsletter+04-03-2026

In conclusion, she says, “The neurocosmetic category is growing rapidly as consumers seek products that address both emotional wellbeing and visible skin results. Actives that calm stress responses, biomimetic lipids that strengthen the barrier, adaptogens, antioxidants, and microbiome‑friendly ingredient technologies are especially influential.”

James adds, “Beauty‑from‑within has also expanded as a consumer preference, with nutricosmetics, calming beverages, and stress‑support supplements providing complementary benefits. Texture‑focused formulations, such as comforting creams, silky serums, and aromatherapeutic oils, are now essential, as sensorial attributes are strongly tied to mood improvement. Ultimately, the most successful neurocosmetic products will help deliver comfort, restore balance, and support a holistic vision of beauty and well-being.”

Https://www.cosmeticsandtoiletries.com/news/event-coverage/article/22961784/2026-alls-showcase-sustainable-innovation-personalized-solutions-and-more-judges-comments?__cf_chl_tk=.Dd35x9L00YbMpEeNAFAYOaI3lZtMEqWvDqVT_yVr3g-1775047084-1.0.1.1-bMZFSQHqOAUO5Gq_4UiYbDtmUgaaqoIFz7Uls8am.zc

Good to see Zenakine is still popular and Active, obviously freshness dropped due to length of time since launch.

https://www.trendhunter.com/trends/croda-beauty

Based on the provided search results, major beauty and cosmetic companies leverage

Trend Hunter to identify, analyze, and track industry trends, innovation, and consumer demand. While Trend Hunter is a consumer insight and trend forecasting platform used by many firms, the provided search results directly link it to trend analysis for companies like L'Oréal, Coty, Johnson & Johnson, and Estée Lauder to guide their product development and digital marketing initiatives.

https://ca.linkedin.com/company/trend-hunter#:~:text=Trend%20Hunter%20is%20the%20world's,NASA%20find%20better%20ideas%2C%20faster.

Shy, MD obviously not concerned.

Very good Aquae, gave me a giggle.